Randomized Controlled Trial Data on Shenfu Injection for Sepsis-Induced Cardiomyopathy

Yaohui Liu published a clinical trial report on figshare in March 2026. The dataset describes a randomized controlled trial involving 152 ICU patients with sepsis, investigating the effect of early Shenfu Injection administration on preventing sepsis-induced cardiomyopathy. The primary outcome was the incidence of SIC within 7 days, with secondary measures including NT-proBNP levels, hemodynamic parameters, and 28-day mortality.

Use Cases

• Analyze the incidence of sepsis-induced cardiomyopathy based on the primary outcome measure from the trial description
• Model biomarker (NT-proBNP) trajectories over time based on the interaction effects described in the results
• Compare treatment and control group outcomes for secondary endpoints like organ function and mortality mentioned in the description

Strengths

• Data is from a randomized controlled trial with 152 patients (76 per group), providing a structured experimental design.
• Includes analysis of multiple clinical endpoints such as NT-proBNP, hemodynamic parameters, and 28-day mortality.
• Published under a CC-BY-4.0 license, allowing for open sharing and reuse.

Limitations

• The dataset is a 440.2 KB PDF report; the underlying raw tabular data is not directly accessible.
• Column-level documentation and sample data are unavailable, requiring manual extraction and interpretation from the text.
• Row count for the raw trial data is unknown, which may limit suitability assessment for direct analysis.

Provenance

Source

figshare, authored by Yaohui Liu.

Collection Method

Data originates from a randomized controlled trial conducted in an ICU setting.

Time Range

The trial period is not specified, but the report was published in 2026.

Freshness

Last updated 2026-03-18 07:39:55; freshness should be verified.

Geography

Spatial coverage is not specified in the provided metadata.